Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114960 | 0.98 | CYP3A4 (0.51) | CYP3A4LMNATRPM8ALDH1A1TP53 | |
| SCHEMBL1114955 | 0.98 | CYP3A4 (0.51) | CYP3A4LMNATRPM8ALDH1A1TP53 | |
| SCHEMBL1114844 | 0.98 | CYP3A4 (0.51) | CYP3A4LMNATRPM8ALDH1A1TP53 | |
| SCHEMBL1114970 | 0.91 | CYP3A4 (0.55) | CYP3A4LMNATRPM8ALDH1A1TP53 | |
| SCHEMBL4061022 | 0.89 | TP53 (0.59) | CYP3A4LMNATRPM8ALDH1A1TP53 | |
| SCHEMBL12679867 | 0.88 | CYP3A4 (0.52) | CYP3A4LMNATRPM8ALDH1A1TP53 | |
| SCHEMBL4058268 | 0.88 | POLB (0.59) | CYP3A4LMNATRPM8ALDH1A1TP53 | |
| SCHEMBL12679863 | 0.87 | CYP3A4 (0.49) | CYP3A4LMNATRPM8ALDH1A1TP53 | |
| SCHEMBL12679894 | 0.87 | CYP3A4 (0.51) | CYP3A4LMNATRPM8ALDH1A1TP53 | |
| SCHEMBL13468874 | 0.87 | CYP3A4 (0.51) | CYP3A4LMNATRPM8ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756039-B1 | Compounds and compositions for delivering active agents | EMISPHERE TECH INC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-1756039-B1 | Compounds and compositions for delivering active agents | EMISPHERE TECH INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8273794-B2 | 7-[isopropyl(phenyl)amino]-7-oxoheptanoic acid, 3-(2-Hydroxy-benzoylamino)-butyric acid, 4-Oxo-4-phenyl-butyric acid, 10-(2-Hydroxy-phenyl)-10-oxo-decanoic acid, 4-(4-Methoxy-phenyl)-4-oxo-butyric acid: promoting the absorption of the active agent | EMISPHERE TECHNOLOGIES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273794-B2 | 7-[isopropyl(phenyl)amino]-7-oxoheptanoic acid, 3-(2-Hydroxy-benzoylamino)-butyric acid, 4-Oxo-4-phenyl-butyric acid, 10-(2-Hydroxy-phenyl)-10-oxo-decanoic acid, 4-(4-Methoxy-phenyl)-4-oxo-butyric acid: promoting the absorption of the active agent | EMISPHERE TECHNOLOGIES, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2279732-A2 | Compounds and compositions for delivering active agents | Emisphere Technologies, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| EP-2279732-A2 | Compounds and compositions for delivering active agents | Emisphere Technologies, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20080255250-A1 | Compounds and Compositions for Delivering Active Agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255250-A1 | Compounds and Compositions for Delivering Active Agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1756039-A4 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2007-05-02 | — | — | EP | disclosed |
| EP-1756039-A2 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005112633-A2 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255250-A1 | Compounds and Compositions for Delivering Active Agents | SERPINB1, ELANE, MMP8 | CYP3A4 3303/4885LMNA 350/4885TRPM8 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.